SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer

The gene for the transducer of transforming growth factor-beta/bone morphogenetic protein signalling SMAD4, a potential suppressor of colorectal carcinogenesis, is located at the chromosomal region 18q21. In order to evaluate the clinical relevance of SMAD4 deletion, gene copy alterations were determined by copy dosage using real-time quantitative PCR in 202 colorectal tumour biopsies from a previous randomised study of adjuvant chemotherapy. Patients with normal SMAD4 diploidy turned out to have a three-fold higher benefit of 5-fluorouracil-based adjuvant chemotherapy with a border line significance (overall survival: 3.23, P=0.056; disease-free survival: 2.89, P=0.045). These data are consistent with the previous observation that patients whose cancer had retention of the 18q21 region had a significantly higher benefit from 5-fluorouracil-based therapy. Moreover, these results may provide a refinement at the gene level of the clinical relevance of 18q21 deletion, thereby suggesting SMAD4 as a predictive marker in colorectal cancer. This data also indicate that integrity of this component of the transforming growth factor-beta/bone morphogenetic protein signalling pathway may be a critical factor for benefit of chemotherapy in patients with colorectal cancer

Effects of Pretreatment Methods on Electrodes and SOFC Performance

Commercially available tapes (anode, electrolyte) and paste (cathode) were choosen to prepare anode-supported cells for solid oxide fuel cell applications. For both anode-supported cells or electrolyte-supported cells, the anode needs pretreatment to reduce NiO/YSZ to Ni/YSZ to increase its conductivity as well as its catalytic characteristics. In this study, the effects of different pretreatments (open-circuit, closed-circuit) on cathode and anodes as well as SOFC performance are investigated. To investigate the influence of closed-circuit pretreatment on the NiO/YSZ anode alone, a Pt cathode is utilized as reference for comparison with the LSM cathode. The characterization of the electrical resistance, AC impedance, and SOFC performance of the resulting electrodes and/or anode-supported cell were carried out. It’s found that the influence of open-circuit pretreatment on the LSM cathode is limited. However, the influence of closed-circuit pretreatment on both the LSM cathode and NiO/YSZ anode and the resulting SOFC performance is profound. The effect of closed-circuit pretreatment on the NiO/YSZ anode is attributed to its change of electronic/pore structure as well as catalytic characteristics. With closed-circuit pretreatment, the SOFC performance improved greatly from the change of LSM cathode (and Pt reference) compared to the Ni/YSZ anode

Novel roles of Akt and mTOR in suppressing TGF-β/ALK5-mediated Smad3 activation

Insulin-like growth factor-I inhibits transforming growth factor-β (TGF-β) signaling by blocking activation of Smad3 (S3), via a phosphatidylinositol 3-kinase (PI3K)/Akt-dependent pathway. Here we provide the first report that the kinase activity of Akt is necessary for its ability to suppress many TGF-β responses, including S3 activation and induction of apoptosis. Wild-type and myristoylated Akts (Akt(WT) and Akt(Myr)) suppress TGF-β-induced phospho-activation of S3 but not Smad2 (S2), whereas kinase-dead Akt1 (Akt1(K179M)) or dominant-negative PI3K enhances TGF-β-induced phospho-activation of both S2 and S3. Using siRNA, rapamycin (Rap), and adenoviral expression for FKBP12-resistant and constitutively active TGF-β type I receptor (ALK5), we demonstrate that mammalian target of Rap (mTOR) mediates Akt1 suppression of phospho-activation of S3. These and further data on Akt1-S3 binding do not support a recently proposed model that Akt blocks S3 activation through physical interaction and sequestration of S3 from TGF-β receptors. We propose a novel model whereby Akt suppresses activation of S3 in an Akt kinase-dependent manner through mTOR, a likely route for loss of tumor suppression by TGF-β in cancers